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ABSTRACT 
 
We previously observed that a chemokine, macrophage inflammatory protein-1 α/CCL3, 
and its receptor, CCR1, were aberrantly expressed in human hepatocellular carcinoma 
(HCC) tissues.  Here, we show that CCL3 and CCR1 are also expressed in two different 
models of this cancer; N-nitrosodiethylamine (DEN)-induced HCC and HCC induced by 
hepatitis B virus surface (HBs) antigen-primed splenocyte transfer to myelo-ablated 
syngeneic HBs antigen transgenic mice.  At 10 months after N-nitrosodiethylamine 
treatment, foci numbers and sizes were remarkably reduced in CCR1- and CCL3-deficient 
mice, compared with wild-type mice, although tumor incidence were marginally but 
significantly higher in CCR1- and CCL3-deficient mice than WT mice.  Of note is that 
tumor angiogenesis was also markedly diminished in CCL3- and CCR1-deficient mice, with 
a concomitant reduction in the number of intratumoral Kupffer cells, a rich source of growth 
factors and matrix metalloproteinases (MMPs).  Among growth factors and MMPs that we 
examined, only MMP9 and MMP13 gene expression was augmented progressively in liver 
of WT mice after DEN treatment.  Moreover, MMP9 but not MMP13 gene expression was 
attenuated in CCR1- and CCL3-deficient mice, compared with wild-type mice. Furthermore, 
MMP9 was expressed mainly by mononuclear cells but not hepatoma cells, and 
MMP9-expressing cell numbers were decreased in CCR1- or CCL3-deficient mice, 
compared with wild-type mice. These observations suggest the contribution of the 
CCR1-CCL3 axis to HCC progression. 
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INTRODUCTION 
 Chemokines are a large family of chemoattractant cytokines for leukocytes1,2 and 
their receptors belong to a family of specific G protein-coupled seven-transmembrane 
domain receptors.3  A wide variety of tumor cells can produce various chemokines either 
constitutively or in response to various stimuli.4  Then, chemokines can recruit various 
types of leukocytes including monocytes/macrophages, lymphocytes, and dendritic cells, 
thereby modulating host responses to tumors.  Moreover, several chemokines can control 
angiogenesis, a process essential for tumor growth, either directly or as a consequence of 
leukocyte infiltration and/or the induction of growth factor production.5  Furthermore, 
some chemokines can guide the growth and the motility of tumor cells,6 thereby affecting 
the processes of tumor progression. 
Hepatocellular carcinoma (HCC) is endemic in Asia, Africa, and southern Europe, 
and ranks as the eighth most common cause of death among total human cancers.  Most 
cases of HCC arise from chronic infection with human hepatitis B virus (HBV) or human 
hepatitis C virus (HCV).7  Although several lines of evidence suggest the potential 
involvement of the chemokine, interleukin-8/CXCL8 in the development of HCC,8-10 other 
chemokines and their receptors may also play a role. In this regard, among various 
chemokine receptors including CCR1, 2, 3, 4, and 5, CXCR1, 2, 3, and 4, we observed 
previously that CCR1 was the only one expressed constitutively in all the 6 human 
hepatoma cell lines that we examined.11 Moreover, CCR1 and its ligand CCL3 were also 
expressed abundantly by tumor cells and to a lesser degree, endothelial cells in human HCC 
tissue.11 These observations suggest that the CCL3-CCR1 axis can exert its effects on tumor 
cells as well as endothelial cells in an autocrine or paracrine manner. 
Chronic HBV or HCV infection can cause continuous and recurrent cycles of 
hepatocyte necrosis and regeneration, resulting in accumulation of mutations.12  
Etiological studies have demonstrated that cigarette smoking increases the risk of HCC 
significantly among patients with chronic HBV infection because it contains N-nitrosamines, 
a potent class of hepatocarcinogen.13,14  Because N-nitrosodiethylamine (DEN), a specific 
N-nitrosamine, can cause HCC with a high frequency in rodents when administered to 
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suckling animals,15,16 the DEN-induced hepatocarcinogenesis model has been used to 
clarify the molecular mechanisms of hepatocarcinogenesis even though most cases of HCC 
arise from chronic infection of HBV or HCV. 
Hence, in order to test the roles of CCL3 and CCR1 in hepatocarcinogenesis, we 
treated both wild-type mice and mice deficient in either CCL3 or CCR1 gene with DEN.  
Here, we provided the first definitive evidence on the contribution of the CCL3-CCR1 axis 
to HCC progression in an animal model. 
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MATERIAL AND METHODS 
 
Reagents  DEN was purchased from Sigma-Aldrich (St. Louis, MO).  Rat anti-mouse 
F4/80 (clone: A3-1) and anti-CD34 (MEC 14.7) monoclonal antibodies were obtained from 
Serotec Ltd (Oxford, United Kingdom).  Rabbit anti-mouse CCR1 antibodies were 
prepared17 and kindly provided by Dr. Kouji Matsushima (University of Tokyo).  Goat 
anti-mouse CCL3 and goat anti-mouse matrix metalloproteinase (MMP) 9 antibodies were 
obtained from R&D Systems, Inc. (Minneapolis, MN). 
 
Mice  Specific pathogen-free C57BL/6 mice were purchased from Charles River Japan 
Co. (Yokohama, Japan) and designated as wild-type (WT) mice.  CCL3-deficient mice18 
were obtained from Jackson Laboratories (Bar Harbor, ME) and CCR1-deficient mice were 
generated as described previously.19 These deficient mice have been backcrossed to 
C57BL/6 mice for at least eight generations and were kept under specific pathogen-free 
conditions. The preparation of HBsAg transgenic mice were described previously.20 These 
mice contain the entire HBV envelope containing region (subtype ayw) under the 
constitutive transcriptional control of the mouse albumin promoter and express the HBV 
small, middle, and large envelope proteins in their hepatocytes.20  All animal experiments 
were performed in compliance with the Guideline for the Care and Use of Laboratory 
Animals on the Takara-machi Campus of Kanazawa University. 
 
DEN-induced hepatocarcinogenesis model  Three-week-old weanling male mice were 
given a single intraperitoneal injection of DEN dissolved in physiologic saline solution at a 
dose of 10 μg/g of body weight.21  Mice were killed 10 months after injection for the 
evaluation of HCC development.  When mice died before this time interval, the liver was 
removed to enumerate the numbers of tumors on the liver surface larger than 1 mm, and to 
be fixed in 10% neutral-formalin buffer for histological analysis.  In another series of 
experiments, mice were killed at the indicated time intervals after DEN treatment for 
histological analysis and extraction of total RNA. 
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Hepatocarcinogenesis model in HBs antigen transgenic mice  Hepatocarcinogenesis 
was induced in HBs antigen transgenic mice by replacing bone marrow cells and 
splenocytes derived from syngeneic non-transgenic mice immunized with HBs antigen, as 
previously described.22  In this model, until 15 months after the splenocyte transfer, mice 
exhibited multiple HCC foci surrounded by non-tumor areas with hepatocytes with an 
atypical nuclear configuration. 
 
Histological analysis  Paraffin-embedded sections were cut at 5 μm and stained with 
hematoxylin and eosin solution.  The numbers and sizes of the neoplastic foci were 
determined by an examiner without any prior knowledge about the experimental procedures, 
according to the method of Pierce23 with some modifications.  The foci number per cm2 
and the percentage of the areas occupied with tumor foci were determined by using NIH 
Image analysis software ver 1.62 (National Institutes of Health, Bethesda, MD). 
 
Immunohistochemical analysis  Rabbit anti-mouse CCR1 (5 μg/ml), goat anti-mouse 
CCL3 (10 μg/ml) or goat anti-mouse MMP9 antibodies (5 μg/ml) were used as the primary 
antibodies.  The sections were further incubated with biotinylated goat anti-rabbit or rabbit 
anti-goat immunoglobulins as the secondary antibodies.  The immune complexes were 
detected by using Vectastain Elite ABC kit and DAB Substrate Kit (Vector Laboratories, 
Burlingame, CA) according to the manufacturer’s instructions.  The slides were then 
counterstained with hematoxylin. The numbers of MMP9-expressing cells were counted on 
five randomly chosen fields from tumor and non-tumor areas in each animal at 400-fold 
magnification by an examiner without any prior knowledge of the experimental procedures. 
 
 Cell proliferation assay  Human hepatoma-derived cell lines, HuH7 and HepG2 cells, 
were maintained in Dulbecco’s modified essential medium (DMEM; Sigma chemical Co., 
St. Louis, MO) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta 
Biological, Norcross, GA) in a humidified incubator at 37ºC in 5% CO2. HuH7 and HepG2 
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cells were seeded into each well of a 96-multi-well plate at a cell density of 1 × 104 and 5 × 
103 respectively, in the presence of recombinant human CCL3 (R&D Systems) at different 
concentrations. Forty-eight hours later, the cell viability was determined using WST-1 
reagent (an MTT analog from Roche Diagnostics Corporation, Boehringer Mannheim) 
according to the manufacturer’s instructions. 
 
Enumeration of F4/80-positive cells  Paraffin-embedded sections were deparaffinized in 
xylene and rehydrated through graded concentrations of ethanol.  After serial treatment 
with 1% (w/v) hydrogen peroxide in methanol, the sections were incubated overnight at 4°C 
with rat anti-mouse F4/80 (1 μg/ml) to detect macrophages/Kupffer cells.  Tissue sections 
were then incubated with biotin-conjugated anti-rat immunoglobulin antibody and treated 
with a Catalyzed Signal Amplification Kit (DAKO) according to the manufacturer’s 
instructions.  The numbers of F4/80-positive cells were counted on five randomly chosen 
fields in tumor as well as non-tumor areas in each animal at 200-fold magnification by an 
examiner without any prior knowledge of the experimental procedures.  The area of each 
field is calculated to be 0.785 mm2 and the numbers of F4/80-positive cells per mm2 were 
calculated on both tumor and non-tumor areas. 
 
CD34 immunohistochemical staining and intratumoral microvessel density (IMVD) 
determination  After deparaffinization of the sections, the slides were treated with 1% 
(v/v) hydrogen peroxide in PBS for 10 min and trypsin for 20 min at 37ºC.  Thereafter, the 
sections were incubated overnight at 4ºC with 5 μg/ml of rat anti-mouse CD34 monoclonal 
antibody, to determine IMVD.24 Tissue sections were further incubated sequentially with 
biotin-conjugated anti-rat immunoglobulin antibody and ABC kit according to the 
manufacturer’s instructions.  The slides were then reacted with a Vectastain DAB 
Substrate Kit and counterstained with hematoxylin.  CD34-positive areas in the tumor 
tissues were defined as the intratumoral vascular areas. Fields of abundant 
neovascularization (hot spots) were found by scanning the sections at low magnification 
(×40 or ×100), and then the microvessel numbers as well as the pixel numbers of 
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CD34-positive areas were determined on five randomly chosen fields in hot spots of each 
animal at 200-fold magnification with the aid of Adobe Photoshop software Ver 7.0. IMVD 
was defined as the average numbers per one filed at 200-fold magnification and the 
percentage area of blood vessels. 
 
Semi-quantitative reverse transcription (RT)-polymerase chain reaction (PCR)  Total 
RNA was extracted from a part of liver with RNAzol B according to the manufacturer’s 
instructions.  After the RNA preparations were further treated with ribonuclease-free 
deoxyribonuclease (DNase) I (Life Technologies Inc., Gaithersburg, MD) to remove 
residual genomic DNA, cDNA was synthesized as described previously.11  Serially 
two-fold diluted cDNA was amplified for β-actin using specific sets of primers (Table I) as 
described previously.11  Thereafter, equal amounts of cDNA products were amplified for 
cytokines, matrix metalloproteinases (MMP), and tissue inhibitors of MMP (TIMP) using 
specific sets of primers based on the reported sequences (Table I), with the indicated cycle 
numbers of 94ºC for 30 second, 55ºC for 1 minute, and 72ºC for 1 minute.  The amplified 
PCR products were fractionated on a 1.5 % agarose gel and visualized by ethidium bromide 
staining.  The intensities of the bands were measured with the aid of NIH Image Analysis 
software, and the ratios to β-actin were determined. 
 
Statistical analysis  Tumor incidence was analyzed by using χ2 test for contingency 
table. All other data were analyzed statistically using one-way ANOVA followed by the 
Fisher’s protected least significance difference test or Mann-Whitney’s U test.  p <0.05 
was considered as statistically significant. 
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RESULTS 
 
CCL3 and CCR1 expression was enhanced progressively in two mouse models of HCC 
development  We previously observed the constitutive expression of both CCL3 and its 
receptor, CCR1, in human HCC tissues.11  Hence, in order to investigate the role of the 
CCL3-CCR1 axis in the HCC development, we first examined whether CCL3 and CCR1 
proteins were expressed in mouse HCC arising in HBs antigen transgenic mice.  We failed 
to detect any CCL3 and CCR1 protein expression in control mouse liver (Fig. 1a-i, vi).  At 
15 months after the HBs antigen-immunized splenocyte transfer, the liver possessed tumor 
areas surrounded by non-tumor areas as described previously.22  In non-tumor portions, a 
small number of hepatocytes were immunostained with anti-CCR1 (Fig. 1a-ii) or anti-CCL3 
antibodies (Fig. 1a-vii).  In contrast, tumor cells, some small bile duct cells, and 
endothelial cells were strongly stained with anti-CCR1 or CCL3 antibodies (Fig. 1a-iii, iv, 
viii, and ix). We next examined the expression patterns of CCL3 and CCR1 in mouse HCC 
induced by a chemical carcinogen, DEN.  CCL3 mRNA expression was faintly detected in 
liver from untreated WT mice, and enhanced progressively, thereafter.  In contrast, CCR1 
gene expression was first detected 4 months after the treatment and was augmented 
progressively, thereafter (Fig. 1b). CCL3 protein was detected immunohistochemically 
occasionally on vascular endothelial cells in untreated mouse liver with no CCR1 
expression (data not shown).   Later than 2 months after DEN treatment, CCL3 protein 
was detected additionally in hepatocytes (Fig. 1c-vi, vii).  At 10 months, CCL3 was 
evident in tumor cells (Fig. 1c-viii) and endothelial cells and some infiltrating mononuclear 
cells (Fig. 1c-ix).  Concomitantly, CCR1 protein was expressed in tumor cells, vascular 
endothelial cells, and some infiltrating mononuclear cells (Fig. 1c-iii, iv).  Thus, CCR1 and 
CCL3 were aberrantly expressed in liver in both hepatocarcinogenesis models. 
 
Effects of CCL3 on human hepatoma cell lines Because CCR1 was expressed by 
hepatoma cells in both mouse and human,11 we next evaluated the effects of CCL3 on 
human hepatoma cell lines. CCL3 inhibited the proliferation of human hepatoma cell lines 
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marginally but significantly at concentrations higher than 100 ng/ml (Fig. 2a, b). Because 
hepatoma cells could produce CCL3 abundantly only in response to interleukin 1 and other 
pro-inflammatory cytokines but not constitutively,11 CCL3 may have some autocrine and/or 
paracrine effects on hepatoma cells. 
 
Important roles of the CCR1-CCL3 axis to DEN-induced hepatocarcinogenesis  In order 
to evaluate the contribution of CCR1 or CCL3 to DEN-induced hepatocarcinogenesis, we 
administered DEN to WT, CCR1-deficient, and CCL3-deficient mice.  At 10 months after 
DEN treatment, there was a marginal but significant differences in terms of HCC incidence 
between CCR1-, and CCL3-deficient mice, compared with WT mice (5/13 cases, WT mice; 
7/10, CCL3-deficient mice; 12/13, CCR1-deficient mice; p<0.05). On the contrary, among 
tumor-bearing mice, the ratios of liver weights to body weights were significantly reduced 
in CCR1- and CCL3-deficient mice, compared with WT mice (Fig. 3a).  Moreover, among 
tumor-bearing mice, the foci number per cm2 and the proportion of tissues occupied with 
tumor were significantly decreased in CCL3- and to a lesser degree, CCR1-deficient mice, 
compared with WT mice (Fig. 3b, c).  Since CCL3 can bind both CCR1 and CCR5,1,2 the 
compensatory effect of CCR5 in CCR1-deficient mice may account for a lesser reduction in 
tumor numbers and sizes in CCR1- than CCL3-deficient mice. Nevertheless, these results 
suggest the important roles of the CCR1-CCL3 axis in DEN-induced hepatocarcinogenesis. 
 
Reduced intratumoral neovascularization and Kupffer cell accumulation in DEN-treated 
CCR1- and CCL3-deficient mice  Reduced tumor foci number in CCR1- or 
CCL3-deficient mice may suggest that neovascularization, a prerequisite for hepatoma 
progression, was impaired in the absence of CCR1 or CCL3. Supporting this notion, both 
the microvessel numbers and the proportion of vascular areas in tumor areas were 
significantly reduced in CCL3- and CCR1-deficient mice, compared with wild-type mice 
(Fig. 4a, b).  Because CCR1 is expressed by various types of cells including macrophages 
and Kupffer cells, a cellular source of various types of growth factors, we next determined 
macrophage and Kupffer cell numbers in HCC foci in WT and gene-deficient mice.  In 
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tumor areas, the numbers of F4/80-positive cells were remarkably depressed in both CCR1- 
and CCL3-deficient mice, compared with WT mice, although the numbers of F4/80-positive 
cells in non-tumor areas were only modestly reduced in CCL3- but not CCR1-deficient 
mice, compared with WT mice (Fig. 4c).   Because F4/80 antigen is expressed by both 
Kupffer cells and blood-derived macrophages, a more specific marker for blood-derived 
macrophages, ER-MP20,25 was used. However, we detected few, if any, ER-MP20-positive 
cells in this model (data not shown). These observations would indicate that the 
CCL3-CCR1 axis has a crucial role also in the accumulation of F4/80-positive Kupffer cells 
into tumor areas in this DEN-induced hepatocarcinogenesis. 
 
Reduced MMP-9 expression in liver from DEN-treated CCR1- and CCL3-deficient mice  
We next investigated the gene expression of potent angiogenic factors, vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor 
(HGF) by RT-PCR.  The gene expression of these angiogenic factors did not change 
significantly in WT mice, at any time after DEN injection that we examined (Fig. 5a).  
Similar results were obtained for the expression of VEGF receptors, Flk-1 and Flt-1 (Fig. 
5a).  Moreover, there were no significant differences in terms of the expression of these 
factors and receptors between WT and CCL3- or CCR1-deficient mice (data not shown).  
Because the balance between MMP and TIMP has crucial roles in the degradation of 
extracellular matrix proteins and subsequent angiogenesis, we next determined the gene 
expression of MMP and TIMP.  Among MMP and TIMP that we examined, MMP9 and 
MMP13 gene expression was augmented progressively in WT mouse liver after DEN 
treatment (Fig. 5b).  Moreover, MMP9 but not MMP13 gene expression was remarkably 
reduced in CCL3- and CCR1-deficient mice, compared with WT mice (Fig. 5c).  We 
further observed that MMP9 proteins were detected in mononuclear cells accumulated 
inside hepatoma tissues arising in both DEN-treated mice (Fig. 5d) and HBs antigen 
transgenic mice (data not shown).  We cannot exclude completely the possibility that HCC 
cells express MMP9 below the detection limit of the present immunohistochemical analysis. 
Nevertheless, it is likely that a major source of MMP9 was mononuclear cells in these 
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models.  Moreover, the numbers of MMP9-positive cells in tumor sites were significantly 
decreased in CCR1- or CCL3-deficient mice, compared with WT mice (Fig. 5d, e). 
Yang  14 
DISCUSSION 
DEN, a potent chemical hepatocarcinogen, acts as an initiator to cause a G-C to 
A-T transition mutation through the methylation of guanine.26  As a result, when suckling 
rodents were given DEN, HCC developed with a high frequency with minimal 
inflammatory changes.15,16  Myelo-depleted HBs transgenic mice developed HCC until 15 
months after the transfer of splenocytes obtained from syngeneic non-transgenic mice that 
had been primed with HBs antigen.22  This hepatocarcinogenesis occurred in the presence 
of chronic hepatitis, as observed in human HCC associated with chronic HBV or HCV 
infection.7  Here, we have provided definitive evidence that CCL3 and CCR1 were 
expressed aberrantly in tumor cells in these two distinctive murine hepatocarinogenesis 
models.  Thus, together with our previous observations on human HCC tissues,11 these 
results suggest the generality of the aberrant expression of CCR1 and CCL3 in HCC tissues. 
 In order to define the roles of the CCL3-CCR1 axis in hepatocarcinogenesis, we 
administered DEN to CCR1- and CCL3-deficient mice as well as WT mice.  Interestingly, 
both CCL3 and CCR1 affected both HCC initiation and tumor progression, but in opposite 
ways. Whereas HCC occurred more frequently in both CCL3- and CCR1-deficient mice 
compared to WT controls, tumor burden (foci number and the proportion of the organ 
occupied by tumor) was dramatically reduced in the former mice. The precise mechanisms 
underlying these effects are not yet clear, however our data point to several intriguing 
possibilities. With regard to disease initiation, we found that recombinant CCL3 stimulation 
of hepatoma cell lines is able to retard cell growth in vitro in a concentration-dependent 
manner. In vivo this could potentially translate into a growth disadvantage for newly 
transformed hepatocarcinoma cells, thereby facilitating surveillance and eradication of these 
cells by immune-mediated mechanisms. The net result would be decreased incidence of 
HCC in WT mice as compared with CCL3- or CCR1-deficient mice. 
 Maeda and colleagues demonstrated that NF-κB activation in hepatocytes could be 
protective for DEN-induced hepatocarcinogenesis, while NF-κB activation in intrahepatic 
hematopoietic cells could promote it.27 Evidence is accumulating to indicate that 
CCR1-mediated signal could activate NF-κB in several types of cells.28,29 Moreover, we 
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observed that CCR1 was expressed by hepatocytes and intrahepatic mononuclear cells. 
Thus, the net effects of the CCR1-CCL3 system may be a balance between its capacities to 
activate NF-κB in these two distinct types of cells. In the initial step when mononuclear 
cells were scarce in liver, the CCR1-CCL3 system may activate NF-κB, mainly in 
hepatocytes, which may account for a lower HCC incidence in WT mice than CCR1- or 
CCL3-deficient mice. Our data indicate that CCL3 and CCR1 are important for 
mononuclear cell accumulation in tumor, consistent with their known chemotactic effects in 
vitro and that some of these cells express a major angiogenic factor, MMP9 whose gene 
expression can be induced by NF-κB activation.30 Because angiogenesis is presumed to be 
crucially required for HCC progression,31 these combined effects could be a major factor 
restricting the size of tumors in CCL3- and CCR1-deficient mice. 
 Although several lines of evidence implied VEGF as an essential mediator 
regulating hypervascularity in HCC,32,33 we failed to detect any changes in VEGF and its 
receptor gene expression during the whole course of DEN-induced hepatocarcinogenesis.  
Moreover, we did not see any differences in VEGF and its receptor gene expression in liver 
between WT and either CCR1- or CCL3-deficient mice.  Thus, it is unlikely that VEGF 
was a main mediator controlling angiogenesis in this model. 
 Evidence is accumulating to indicate that the balance between MMP and their 
inhibitors, TIMP, has crucial roles in tumor progression by inducing tumor angiogenesis and 
altering the extracellular environment more suitable for tumor cell establishment and 
growth.34 Moreover, several cDNA microarray analyses on human HCC have revealed that 
the expression of some MMPs were enhanced in HCC tissues, compared with non-tumor 
portion.35,36 These observations prompted us to examine MMP and TIMP gene expression 
by RT-PCR analysis. Among MMPs and TIMPs that we examined, only MMP9 and 
MMP13 gene expression were augmented progressively after DEN treatment, and MMP9 
but not MMP13 gene expression was significantly attenuated in liver of DEN-treated 
CCR1- and CCL3-deficient mice, compared with WT mice. Crucial involvement of MMP9 
in angiogenesis has been substantiated by the observations on MMP9-deficient mice.37 
Moreover, MMP9-positive cells appeared even in pre-malignant lesion in the absence of 
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neovascularization (our unpublished data) and MMP9-positive cell numbers in tumor areas 
were significantly reduced in CCR1- or CCL3-deficient mice, compared with WT mice. 
Thus, it is likely that the reduction in MMP9 expression can account for attenuated tumor 
angiogenesis in CCR1- and CCL3-deficient mice. 
 Several lines of evidence indicate that bone marrow-derived progenitors can direct 
neovascularization.38,39  Moreover, CCL3 exhibits a potent mobilizing activity for 
hematopoietic stem cells40 by predominantly interacting with CCR1.41  Furthermore, 
MMP9 was required for hematopoietic stem cell mobilization from bone marrow to other 
organs including liver.42,43 We also detected the presence of c-kit-positive stem cells 
co-expressing CCR1 in the tumor foci of DEN-treated but not untreated WT mice (our 
unpublished data).  Thus, it is tempting to speculate that HCC-derived CCL3 induced 
hematopoietic stem cell mobilization into liver, in collaboration with MMP9 and that 
hematopoietic stem cells can induce tumor angiogenesis, in concert with MMP9. 
 Several gene loci, which have been identified as the loci determining the sensitivity 
of hepatocytes to DEN, are localized on mouse chromosomes 1, 2, 7, 8, and 12.44  The 
present results suggest that both CCR1 and CCL3 have profound effects on the progression 
of DEN-induced hepatocarcinogenesis.  Because CCR1 and CCL3 genes are localized on 
mouse chromosomes 9 and 11, respectively, these genes must be hitherto unidentified genes 
that determine the sensitivity to DEN-induced hepatocarcinogenesis.  Moreover, given that 
both CCL3 and CCR1 were expressed by HCC cells, it is likely that the CCL3-CCR1 axis 
has some direct effects on HCC cells and can eventually regulate HCC progression induced 
by DEN treatment.  Furthermore, aberrant expression of CCL3 and CCR1 was also 
observed in human HCC tissues11 as well as in our murine hepatocarcinoma models in 
DEN-treated mice and HBs transgenic mice.  Thus, CCL3 and CCR1 may be involved in 
the progression of HCC in general.  If so, detailed molecular analysis on DEN-treated 
CCL3- or CCR1-deficient mice will shed a novel light on the molecular pathogenesis of 
HCC. 
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Table I - The sequences of the primers and the conditions used for RT-PCR analysis 
 Sense primer Antisense primer Cycles Product 
(bp) 
β-actin TGTGATGGTGGGAATGGGTCAG TTTGATGTCACGCACGATTTCC 25 514 
CCR1 TTTTAAGGCCCAGTGGGAGTT TGGTATAGCCACATGCCTTT 32 475 
CCL3 ATCATGAAGGTCTCCACCAC TCTCAGGCATTCAGTTCCAG 32 284 
VEGF CTGCTGTACCTCCACCATGCCAAGT CTGCAAGTACGTTCGTTTAACTCA 35 509 
bFGF ACACGTCAAACTACAACTCCA TCAGCTCTTAGCAGACATTGG 35 295 
HGF GCTTGGCATCCACGATGTTC CCCTCACATGGTCCTGATCC 35 387 
Flt-1 TTAGGGGGTTCTCCATACCC TATCTTCATGGAGGCCTTGG 35 531 
Flk-1 CAGCTTCCAAGTGGCTAAGG CATAATGGAATTTGGGGTCG 35 620 
MMP2 GAGTTGGCAGTGCAATACCT GCCGTCCTTCTCAAAGTTGT 35 666 
MMP9 AGTTTGGTGTCGCGGAGCAC TACATGAGCGCTTCCGGCAC 35 754 
MMP13 CTGGTCTTCTGGCACACGCT GCAGCGCTCAGTCTCTTCAC 35 610 
TIMP-1 CTGGCATCCTCTTGTTGCTA AGGGATCTCCAGGTGCACAA 35 583 
TIMP-2 AGACGTAGTGATCAGGGCCA GTACCACGCGCAAGAACCAT 35 490 
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LEGENDS TO FIGURES 
 
Figure 1 - Aberrant expression of CCR1 and CCL3 in hepatocarcinogenesis 
(a) Immunohistochemical detection of CCR1 and CCL3 in HBs antigen transgenic mice.  
Immunohistochemical analysis using anti-CCR1 (i-iv), anti-CCL3 antibodies (vi-ix), or 
species-matched control antibodies (v, x) was performed on control liver (i, vi) and, 
non-tumor (ii, vii) and tumor portions (iii, iv, v, viii, ix and x) in liver in HBs antigen 
transgenic mice at 15 months after splenocyte transfer as described in Material and Methods.  
Representative results from three individual animals are shown here.  The arrows in iii and 
viii indicate positively-stained bile duct and endothelial cells.  iv and ix indicate 
positively-stained HCC cells.  Original magnification, ×100 (i and vi), ×200 (ii, iii, vii, 
viii), ×400 (iv, v, ix, x). Scale bars, 50 μm. 
(b) CCR1 and CCL3 mRNA expression in liver after DEN treatment.  RT-PCR was 
performed on total RNA extracted from WT mice liver at 0, 2, 4, 6, and 10 months after 
DEN treatment, as described in Material and Methods.  Representative results from five 
individual experiments are shown here. 
(c)  Immunohistochemical analysis of CCR1 and CCL3 protein in WT mice liver after 
DEN treatment.  Liver tissues were obtained from WT mice at 2 (i, vi), 6 (ii, vii), and 10 
months after DEN treatment (iii, iv, v, viii, ix, and x).  Immunohistochemical analysis was 
performed using anti-CCR1 (i-iv), anti-CCL3 antibodies (vi-ix), or species-matched control 
antibodies (v, x) as described in Material and Methods.  Arrows in iii and viii indicate 
positively-stained HCC cells while an arrow in iv indicates positively-stained endothelial 
cells.  The arrows and the inset (scale bar, 10 μm) in ix indicate infiltrating lymphocytes.  
Representative results from 3 animals from each time point are shown here.  Original 
magnification, ×100 (i, ii), ×200 (vi, vii), ×400 (iii to v and viii to x). Scale bars, 50 μm. 
 
Figure 2 - The effects of CCL3 on hepatoma cell lines.  
Either HuH7 (a) or HepG2 (b) cells were incubated in the presence of the indicated 
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concentrations of CCL3, and cell proliferation rates were assessed as described in Material 
and Methods. Similar experiments were repeated three times and representative results are 
shown here with error bars as SEM (n=3). 
 
Figure 3 - Attenuated tumor formation in CCR1- and CCL3-deficient mice at 10 months 
after DEN treatment.  Livers were obtained from mice at 10 months after DEN treatment 
to examine the presence of HCC foci.  Among tumor-bearing mice of each strain (WT 
mice, n = 5; CCL3-deficient mice, n = 7; CCR1-deficient mice, n = 12), the relative ratios 
of liver to body weights (a), foci number per cm2 (b), and the proportion of tissues occupied 
with tumor foci (c) were determined as described in Material and Methods.  Each value 
represents mean ± SEM.  * indicate p<0.05, compared with WT mice. 
 
Figure 4 - Reduced IMVD and Kupffer cell numbers in liver of DEN-treated CCR1- and 
CCL3-deficient mice.  (a and b) Livers were obtained from each strain at 10 months after 
DEN treatment and processed for immunostaining with anti-CD34 antibodies. IMVD was 
defined as the microvessel numbers per field at 200-fold magnification (a) or the 
proportions of CD34-positive areas (b) as described in Material and Methods, each value 
represents mean ± SEM (n=5). * indicate p<0.05, compared with WT mice. 
(c) Livers were obtained from each strain at 10 months after DEN treatment and processed 
for immunostaining with an anti-F4/80 monoclonal antibody. The numbers of 
F4/80-positive cells in non-tumor and tumor areas were determined as described in Material 
and Methods. Each value represents mean ± SEM (n=5). *, p<0.05; **, p<0.01. 
 
Figure 5 - (a to c) Gene expression of angiogenic factors and their receptors, and matrix 
metalloproteinses.  (a) RT-PCR for the genes of angiogenic factors and VEGF receptors 
was performed on total RNA extracted from WT mice liver at the indicated time intervals (0, 
2, 4, 6 and 10 months) after DEN treatment, as described in Material and Methods. The 
ratios of each gene to β-actin were determined. Each value represents mean ± SEM (n=5). 
m, month. 
Yang  26 
(b) RT-PCR for MMP and TIMP genes was performed on total RNA extracted from WT 
mice liver at 0, 2, 4, 6, and 10 months after DEN treatment, as described in Material and 
Methods.  The ratios of each gene to β-actin were determined. Each value represents mean 
±SEM (n=5) with ** indicating p<0.01, compared with 0 month. m, month. 
(c) RT-PCR for the indicated genes was performed on total RNA extracted from tumor 
bearing liver of WT, CCR1-, and CCL3-deficient mice at 10 months after DEN treatment in 
a separate experiment from the experiments shown in Figure 5a and b, as described in 
Material and Methods. The ratios of each gene to β-actin were determined.  Each value 
represents mean ± SEM (n=5) with ** indicating p<0.01, compared with WT mice. 
(d) Immunohistochemical detection of MMP9-positive cells in liver after DEN treatment.  
Immunohistochemical analysis was performed on liver tissues obtained from WT, CCL3- or 
CCR1-deficient mice at the indicated time intervals after DEN treatment, as described in 
Material and Methods. Representative results from 6 individual animals are shown here. 
Original magnification, ×400.  Scale bars, 50 μm. 
(e) The numbers of MMP9-positive cells in WT, CCL3- or CCR1-deficient mice liver at 10 
months after DEN treatment. All values and bars represent the mean and SEM calculated on 
the results from 6 individual animals, respectively.  **, p<0.01. 
 





